Chimeric Antigen Receptor (CAR) modified Cytokine Induced Killer (CIK) cells

Why use CIK cells?

  • NOT an NK or T cell
  • Ideal for Allogeneic cell therapy
    • Simple and robust manufacturing process
      • Successfully produced at 3 independent facilities
    • Dual killing mechanisms
    • Persist long-term in vivo
    • Resistant to inducing GvHD
      • Allows for significant tissue mismatch
    • Overcomes persistence/durability of response problems seen with other allo therapies
    • Proven safe and efficacious in clinical trials

*BLOOD (2008) 112(6):2563

Highly efficient proprietary non-viral gene transfer technology: Sleeping Beauty 100X (SB100X)**

  • CoImmune holds exclusive world-wide license
  • Simple electroporation step
  • Consistently high gene transfer rate (60%-90% genetically modified cells)
  • Faster next generation product development timelines achievable with no need for virus stocks

**Crit. Rev. in Biochem and Mol Bio (2017) 52(4):355–380

Streamlined manufacturing process

Production based on material from healthy donors reduces lot-to-lot variability compared to autologous CAR-T therapies

CAR-CIK therapy offers numerous advantages over traditional CAR-T therapy

CAR-CIK Products Approved CAR-T Products
Allogeneic (healthy donors, requires only low-resolution tissue match enabling off-the-shelf availability) Autologous (complex logistics and supply chain)
Little to no toxicity (allows repeat dosing, no SAEs to date) Toxicity limits patient eligibility
Dual killing mechanisms (antigen dependent and independent) Single killing mechanism
Inexpensive non-viral genetic modification (more efficient than virus) Viral genetic modification significantly increases COGs, potential safety issues
Simplified manufacturing process (multiple doses/run) No economy of scale

Compared to other allogeneic CAR-Ts under development, CAR-CIK products are resistant to GVHD and do not require additional genetic engineering to reduce immunogenicity or immunosuppression of the patient